Visgenx to Present at the 9th Annual Retinal Cell and Gene Therapy Innovation Summit
Visgenx, a retinal gene therapy Company
Will address the use of Gene Therapy to increase retinal concentrations of Long Chain and Very Long Chain Polyunsaturated Fatty Acids as a treatment for dry AMD
The Innovation Summit is sponsored by the Foundation for Fighting Blindness and it is a great forum to present new data on the gene therapy (VGX-0111) we are developing for the treatment of dry AMD.”
SAN DIEGO, CALIFORNIA, USA, April 29, 2024 /EINPresswire.com/ -- Visgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, today announced that the Company’s Chief Science Officer and Co-Founder, Marty Emanuele, Ph.D., will present at the 9th Annual Retinal Cell and Gene Therapy Innovation Summit on May 3rd in Seattle, Washington. — Marty Emanuele
“The Innovation Summit is sponsored by the Foundation for Fighting Blindness and it is a great forum to present new data on the gene therapy (VGX-0111) we are developing for the treatment of dry AMD,” stated Dr. Emanuele.
The Company’s lead product VGX-0111, is a candidate gene therapy being developed for the treatment of dry AMD. VGX-0111 utilizes the ELOVL2 gene, which is required for the biosynthesis of long chain and very long chain fatty acids (LC/VLC-PUFA) necessary for the function and survival of photoreceptor cells. ELOVL2 expression declines with age and may be an underlying pathology of dry AMD. VGX-0111 is intended to restore healthy levels of ELOVL2 expression and thereby reestablish physiologically normal LC/VLC-PUFA retinal levels, resulting in the slowing or halting of vision loss from dry AMD.
ABOUT VISGENX, INC.
Visgenx, Inc. is a biotechnology company focused on developing gene-based therapeutics for degenerative retinal diseases. Visgenx’ initial product is VGX-0111, a gene therapy candidate being developed for the treatment of dry Age-related Macular Degeneration (AMD). Approximately 200 million people suffer from dry AMD globally and it is a leading cause of blindness. VGX-0111 is based on the ELOVL2 gene, which is required for the biosynthesis of lipids necessary for the function and survival of retinal cells. ELOVL2 expression declines with age resulting in declining LC/VLC-PUFA levels which may be an underlying pathology of dry AMD. VGX-0111 is intended to restore a normal level of ELOVL2 expression thereby slowing or halting the vision loss resulting from dry AMD. For more information on Visgenx, visit www.visgenx.com.
Forward Looking Statements
This press release contains forward-looking statements related to Visgenx, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995, that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the potential for VGX-0111 as a treatment for Dry AMD. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements include that the therapy may not be effective at treating Dry AMD. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.
###
@ 2024 Visgenx, Inc. All Rights Reserved.
William Pedranti
Visgenx
william@visgenx.com
Visit us on social media:
LinkedIn
Other
Powered by
Distribution channels:
Chemical Industry, Healthcare & Pharmaceuticals Industry, Science, Technology
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
